ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

YPSODOSE – THE CLINIC-READY 10 ML PATCH INJECTOR

Ypsomed's Christian Esser Wiesemann provides the latest insights into the prefilled and pre-assembled YpsoDose patch injector, which is now available for clinical trials.

EXTENDING PATIENT-FRIENDLY DRUG DELIVERY TO HIGH-VOLUME WEARABLE DEVICES

Iris Schnitzler discusses the benefits of on-body delivery systems, including the flexibility and convenience they bring to patients managing chronic conditions, and how the Sorrel platform overcomes some of the inherent complexities and challenges of developing such a device. Dr Schnitzler then goes on to speak with Bas van Buijtenen and Andrei Yosef about the Sorrel platform and how its integration within LTS supports the company’s fundamental objectives of enabling partners and empowering patients.

THE VERTIVA™ ON-BODY DELIVERY SYSTEM: EXPANDING OPPORTUNITIES IN HOME-BASED CARE

Adam Stops introduces Vertiva™, Stevanato Group’s next-generation on-body delivery system platform, and discusses how it meets the needs of pharma companies looking to deliver large-volume doses in a patient-centric manner.

Lipid Nanoparticles Development Europe – Amsterdam

17th Nov 2023 - 19th Nov 2023

Lipid Nanoparticles Development Europe – Amsterdam

The 2nd Lipid Nanoparticle Development Europe Summit is committed to equipping you with actionable takeaways across end-to-end characterisation, biodistribution, formulation and scale up to supercharge your LNP pipeline development with therapeutic promise to patients. Built in collaboration with CPI, Pfizer, GSK, this 3-day summit will reunite 100+ senior leaders, sharing exclusive data to help you maximise this non-viral delivery system's potential.

A NEW FRONTIER: SELF-ADMINISTRATION OF LYOPHILISED, LARGE-VOLUME SUBCUTANEOUS BIOLOGICS

Enable Injections

A NEW FRONTIER: SELF-ADMINISTRATION OF LYOPHILISED, LARGE-VOLUME SUBCUTANEOUS BIOLOGICS

Mehul Desai and Daniel Waites discuss the pros and cons of lyophilisation for biologic injectable drugs, and how Enable Injections’ enFuse device can provide an answer to the challenges of self-injection of large-volume and lyophilised biologics.

PRODUCT SHOWCASE: COMPLETE SYSTEM FOR STANDARD-COMPLIANT TESTING OF WEARABLE INJECTORS

PRODUCT SHOWCASE: COMPLETE SYSTEM FOR STANDARD-COMPLIANT TESTING OF WEARABLE INJECTORS

Specifically tailored to on-body delivery systems (OBDSs) / wearable injectors, ZwickRoell showcases its customised, comprehensive solution for performing functional tests in accordance with the ISO 11608-6 standard.

SUSTAINABLE DESIGN OF A DRUG DELIVERY DEVICE FOR BIOPHARMACEUTICALS

SUSTAINABLE DESIGN OF A DRUG DELIVERY DEVICE FOR BIOPHARMACEUTICALS

Maike Wolf and Marie Stockton discuss how sustainability is a fundamental strategic priority for Gerresheimer. They also highlight how eco-design principles have been applied to the development of an on-body injector for subcutaneous delivery of biopharmaceuticals.

COMPARISON OF MECHATRONIC VS MECHANICAL WEARABLE DRUG DELIVERY SYSTEMS

COMPARISON OF MECHATRONIC VS MECHANICAL WEARABLE DRUG DELIVERY SYSTEMS

Thomas Mayer, Nicolas Bailo and Martin Liniger highlight some of the key challenges that mechanical and mechatronic drug delivery systems must overcome when delivering large volumes of biologics subcutaneously and explain the solutions that Sonceboz has considered during the development process of the company’s large-volume injector.

CHRONIC PATIENTS AT THE CENTRE OF LARGE-VOLUME SC DELIVERY WITH A SUSTAINABLE ON-BODY INJECTOR

CHRONIC PATIENTS AT THE CENTRE OF LARGE-VOLUME SC DELIVERY WITH A SUSTAINABLE ON-BODY INJECTOR

Cécile Gross and Mark Tunkel discuss the role of patient-centricity in the development of Nemera’s sustainable on-body injector platform.

Technology Showcase: CCBio’s Felice Dose – Simplifying Subcutaneous Infusion

Technology Showcase: CCBio’s Felice Dose – Simplifying Subcutaneous Infusion

CCBio showcases Felice Dose, a revolutionary on-body injector (OBI) designed to address the challenges of traditional IV injections and SC drug administration.

INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES

INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES

Roger Bohannan discusses the capabilities and design challenges of connected drug delivery devices.

INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT

Dave Beckstoffer

INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT

Dave Beckstoffer discusses the often overlooked importance of including motion system design considerations from the very earliest stages of wearable injector development, and how doing so can reduce costs, shorten timelines and improve patient outcomes.

DIRECTIONS FOR WEARABLE ON-BODY INJECTOR SYSTEMS AND BEYOND

DIRECTIONS FOR WEARABLE ON-BODY INJECTOR SYSTEMS AND BEYOND

Matt Parker, Karthik Chellappan and David Cottenden discuss the current state of play for large-volume injection and look into the challenges that on-body delivery systems currently in development will need to overcome to find success in a changing marketplace.

WOULD YOU LIKE TO GO LARGE? KEY CONSIDERATIONS FOR LARGE-VOLUME INJECTORS

WOULD YOU LIKE TO GO LARGE? KEY CONSIDERATIONS FOR LARGE-VOLUME INJECTORS

Malcolm Boyd discusses the factors that need to be considered early in the development of large-volume injectors, which will have a major influence on the performance, usability and cost of a device.

REUSABLE WEARABLE INJECTORS: LESSONS FROM IN VITRO DIAGNOSTICS

REUSABLE WEARABLE INJECTORS: LESSONS FROM IN VITRO DIAGNOSTICS

Thomas James explores how insights from the development of successful in vitro diagnostic instruments can help guide the evolution of wearable injectors.

BD INNOVATION FOR SUBCUTANEOUS DELIVERY OF LARGE-VOLUME COMPLEX BIOLOGICS

Beth McBride DiLauri

BD (Becton Dickinson & Company)

BD INNOVATION FOR SUBCUTANEOUS DELIVERY OF LARGE-VOLUME COMPLEX BIOLOGICS

Beth McBride DiLauri summarises the results of a clinical study on the BD Libertas™ Wearable Injector. The results position the device as a viable alternative to traditional intravenous administration.

HIGH-THROUGHPUT SCREENING TO ACCELERATE NANOMEDICINE DISCOVERY

INDUSTRIALISATION

Dr Ben Knappett

HIGH-THROUGHPUT SCREENING TO ACCELERATE NANOMEDICINE DISCOVERY

Ben Knappett discusses how the successful combination of microfluidics with automation can provide rapid and cost-effective high-throughput lipid nanoparticle technology formulation screening, and how this approach could play a significant role in advancing the development of new nanotherapies.

DFM & DFA: THE DIFFERENCES, BENEFITS AND HOW TO IMPLEMENT THEM

DFM & DFA: THE DIFFERENCES, BENEFITS AND HOW TO IMPLEMENT THEM

Phil Sampey discusses the principles associated with design-for-manufacture (DFM) and design-for-assembly (DFA) methodologies as applied to drug delivery device design, giving an overview of what each involves and key areas of focus to ensure that the full benefits of these approaches can be realised.

SUCCESSFUL INDUSTRIALISATION REQUIRES SOLID FOUNDATIONS

INDUSTRIALISATION

West Pharmaceutical Services

SUCCESSFUL INDUSTRIALISATION REQUIRES SOLID FOUNDATIONS

Jennifer Riter and Victoria Morgan discuss the importance of choosing the right containment system at the start for successful industrialisation of an injectable drug product.

STREAMLINING DRUG DELIVERY DEVICE DEVELOPMENT FOR INDUSTRIALISATION SUCCESS

INDUSTRIALISATION

STREAMLINING DRUG DELIVERY DEVICE DEVELOPMENT FOR INDUSTRIALISATION SUCCESS

Hans Arts, Jan-Willem Den Hollander and Ron Cisliek discuss the value of bringing an industrialisation partner on board early in product development and how working with a single manufacturing specialist can preserve insights and learnings throughout the product development lifecycle and deliver additional value and quality.

HOW A FLEXIBLE APPROACH TO AUTOINJECTOR ASSEMBLY EQUIPMENT CAN DELIVER A COMPETITIVE ADVANTAGE

INDUSTRIALISATION

Mads Keinicke Hansen

Stevanato Group

HOW A FLEXIBLE APPROACH TO AUTOINJECTOR ASSEMBLY EQUIPMENT CAN DELIVER A COMPETITIVE ADVANTAGE

Mads Keinicke Hansen presents an overview of the company’s Standard Autoinjector Assembly Machine platform, providing an in-depth examination of its key features and advantages to illustrate how it is transforming autoinjector assembly processes in the pharmaceutical industry.

RFID-BASED UNIT-LEVEL TRACEABILITY: COULD IT BE THE KEY TO OPERATIONAL EXCELLENCE FOR FILL-FINISH LINES?

INDUSTRIALISATION

BD (Becton Dickinson & Company)

RFID-BASED UNIT-LEVEL TRACEABILITY: COULD IT BE THE KEY TO OPERATIONAL EXCELLENCE FOR FILL-FINISH LINES?

Yacine Haddadi and Herve Soukiassian look at how the company’s track & trace model can help manufacturers improve their fill-finish operations.

ENTERING THE UK MARKET: A GUIDE FOR US MEDICAL DEVICES COMPANIES

IMed Consultancy

ENTERING THE UK MARKET: A GUIDE FOR US MEDICAL DEVICES COMPANIES

Matthew Burton discusses the new EU Medical Device Registration and offers a guide for the UK Responsible Person within companies.

CONNECTING PHARMA: INSIGHTS FROM AUTOMOTIVE INDUSTRY EXPERIENCE

EdgeOne Medical

CONNECTING PHARMA: INSIGHTS FROM AUTOMOTIVE INDUSTRY EXPERIENCE

Jim McGough talks with Guy Furness about the current state and future of connectivity in drug delivery and pharma more broadly. In an enlightening discussion, Mr McGough shares insights from his time pioneering connectivity in the automotive industry at Volkswagen Group and how those lessons might apply to pharma, as well as considering what might be holding the industry back from going full steam ahead on connectivity and how that might change over the next decade.

DIGITAL TWIN IN THE PHARMACEUTICAL SUPPLY CHAIN

DIGITAL TWIN IN THE PHARMACEUTICAL SUPPLY CHAIN

Gerresheimer’s Ali Badiei explains the role of digital twin technology and its integration into the pharmaceutical supply chain, highlighting an innovative approach to ensuring drug identity and quality.

REIMAGINING AUTOINJECTOR CONNECTIVITY

Dr Kate Hudson-Farmer

REIMAGINING AUTOINJECTOR CONNECTIVITY

Kate Hudson-Farmer and Simon Hall discuss a new smartphone-based connectivity solution for autoinjectors that requires no additional hardware and works with most autoinjectors and smartphones.

Real-World Evidence in the Age of Digital Health – Unlocking Value for Pharmaceutical Companies

Ventsislav Dobrev

Real-World Evidence in the Age of Digital Health – Unlocking Value for Pharmaceutical Companies

Ventsislav Dobrev, Philippe Müller and Rafael Weiler explore how real-world evidence in the age of digital health can help unlock value for pharmaceutical companies.

TAKING A PATIENT-CENTRIC APPROACH TO CANCER CARE THROUGH IMMUNOTHERAPY

Dr Corinne Fechant

TAKING A PATIENT-CENTRIC APPROACH TO CANCER CARE THROUGH IMMUNOTHERAPY

Corinne Fechant and Laura Hilliquin highlight the role digital health solutions can play in supporting patient self-administration for the increasing number of immunotherapies for cancer treatment.

LESSONS FROM MARKETED MEDICAL DEVICES TO ENHANCE CONNECTED DRUG DELIVERY

Fallyn Flaherty-Earp

LESSONS FROM MARKETED MEDICAL DEVICES TO ENHANCE CONNECTED DRUG DELIVERY

Fallyn Flaherty-Earp looks at what medical device manufacturers can learn from connected devices already on the market and discusses the opportunities electronic inks can provide for the development of innovative therapies for the treatment of chronic diseases.

EMPOWERING PATIENTS FOR SELF-CARE WITH NFC CONNECTIVITY

NXP Semiconductors

EMPOWERING PATIENTS FOR SELF-CARE WITH NFC CONNECTIVITY

Sylvia Kaiser-Kershaw looks at how near-field communication technology can be used to add connectivity to medical devices, empowering patients to self-administer medication.

Interview with Arnaud Guillet & Fanny Sellier

Interview with Arnaud Guillet & Fanny Sellier

Arnaud Guillet and Fanny Sellier talk with Guy Furness about how Biocorp has become a key player in the field of connected drug delivery, discuss the current landscape for connectivity in drug delivery and update us on its two major parenteral products – Mallya and Injay – as well as looking forward to the launch of the company’s next generation of connected drug delivery solutions.

THE POTENTIAL OF CONNECTIVITY AND MONITORING IN MESH NEBULISERS

Carolina Dantas

THE POTENTIAL OF CONNECTIVITY AND MONITORING IN MESH NEBULISERS

Carolina Dantas and Ulf Krueger review the current connectivity and remote monitoring capabilities in mesh nebulisers – and their potential to impact patients’ healthcare journeys and the clinical development of inhaled therapies.

COLLABORATIVE INNOVATION IN CONNECTED AUTOINJECTORS: HIGH-IMPACT ADHERENCE SOLUTIONS

Chelsea Williams

COLLABORATIVE INNOVATION IN CONNECTED AUTOINJECTORS: HIGH-IMPACT ADHERENCE SOLUTIONS

Chelsea Williams, Nils Weber and Gene Rhode Fuensalida Pantig discuss the potential of collaborative innovation in connected drug delivery when it comes to creating high-impact, low-touch adherence solutions.

THE IRONIES OF AUTOMATION: LESSONS FOR REMOTE PATIENT MONITORING

THE IRONIES OF AUTOMATION: LESSONS FOR REMOTE PATIENT MONITORING

Dan Lock considers how to overcome potential pitfalls and make the most of remote patient monitoring for the benefit of both patient care and clinical trials.

TREATING THE NEXT GENERATION: THE UNTAPPED POTENTIAL OF ORALLY DISPERSIBLE FILMS

Dr Keat Theng Chow

TREATING THE NEXT GENERATION: THE UNTAPPED POTENTIAL OF ORALLY DISPERSIBLE FILMS

Keat Theng Chow explores the latest scientific thinking on orally dispersible film formulation, and how these advancements could open a new chapter in paediatric patient compliance.

CHALLENGES AND ACHIEVEMENTS OF TIO<sub>2</sub> REPLACEMENT IN HARD CAPSULES

Susana Ecenarro Probst

CHALLENGES AND ACHIEVEMENTS OF TIO₂ REPLACEMENT IN HARD CAPSULES

Susana Ecenarro Probst looks at the issues arising in replacing TiO₂ in hard capsules and introduces Qualicaps' alternative hard capsule formulation.

PRODUCT SHOWCASE: Optimising Gastric Resistance in Complex Oral Drug Products with Novel, Functional, Ready-To-Fill Capsules

Dr Bettina Hölzer

PRODUCT SHOWCASE: Optimising Gastric Resistance in Complex Oral Drug Products with Novel, Functional, Ready-To-Fill Capsules

Evonik showcases its novel, functional, ready-to-fill capsules portfolio, EUDRACAP^®, explaining how its role in optimising gastric resistance in complex oral drug products.

POWDER CHARACTERISATION FOR PHARMACEUTICALS: BEYOND STANDARDS

Dr Aurelien Neveu

POWDER CHARACTERISATION FOR PHARMACEUTICALS: BEYOND STANDARDS

Aurélien Neveu, Marco Lupo and Filip Francqui discuss the limitations of current standardised procedures for assessing the properties of pharmaceutical powders and how Granutools’ instruments – GranuPack and GranuHeap – offer a significant improvement.

STRATEGIES FOR STREAMLINING THE DEVELOPMENT OF COMPLEX ORAL DRUG PRODUCTS

Dr Aruna Railkar

Quotient Sciences

STRATEGIES FOR STREAMLINING THE DEVELOPMENT OF COMPLEX ORAL DRUG PRODUCTS

Aruna Railkar presents three case studies – one involving solubility enhancement, one modified release, and a paediatric dosage form – to illustrate the formulation challenges in complex drug programmes.

1
2
3
…
35
Next

See what ondrugdelivery's readers and contributors think

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Top